An open-label, single-arm, Phase II study investigating the efficacy of PBI-4050 in patients with type 2 diabetes and multi-organ fibrosis

Trial Profile

An open-label, single-arm, Phase II study investigating the efficacy of PBI-4050 in patients with type 2 diabetes and multi-organ fibrosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2016

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2016 Preliminary data expected in H2 2016, as per ProMetic media release.
    • 12 Nov 2015 According to a ProMetic Life Sciences media release, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has cleared the clinical trial application (CTA) for PBI-4050 in patients suffering from a condition associated with type 2 diabetes and severe multi-organ fibrosis.
    • 02 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top